Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 8, 2016European Heart JournalOpen Access

Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial

View Full Paper
Ask AI
Bookmark
Share

Key result

Tocilizumab attenuates inflammation and reduces troponin T release versus placebo in NSTEMI patients.

Why the study?

Does a single dose of tocilizumab reduce inflammation and troponin T release in patients with NSTEMI?

Population

Patients with non-ST-elevation myocardial infarction (NSTEMI)

Comparison

Single dose of tocilizumab vs Placebo

Design

RCT, randomized, double-blind

Authors

OKOla KlevelandSt Olav's University HospitalGKGabor KunsztInstitució Catalana de Recerca i Estudis AvançatsMBMarte BratlieRemovAid (Norway)

Discussion

Loading...

Member takes

Implication

Does not alter NSTEMI management; leaves open whether IL-6 inhibition improves clinical outcomes.

Key Points

  • Investigate the effect of tocilizumab on inflammation and troponin T release in NSTEMI patients.
  • Double-blind, randomized, placebo-controlled design
  • Administration of a single dose of tocilizumab
  • Focused on patients with non-ST-elevation myocardial infarction
  • Tocilizumab significantly attenuated the inflammatory response
  • Reduced primarily PCI-related troponin T release in patients

Structured PICO

Does a single dose of tocilizumab reduce inflammation and troponin T release in patients with NSTEMI?

P
Population
Patients with non-ST-elevation myocardial infarction (NSTEMI)
I
Intervention
Single dose of tocilizumab (interleukin-6 receptor antagonist)
C
Comparator
Placebo
O
Outcome
Inflammation and troponin T releasesurrogate

A single dose of tocilizumab attenuates inflammation and PCI-related troponin T release in patients with NSTEMI.

Cite This Study

Kleveland et al. (2016) studied this question. Tocilizumab attenuated the inflammatory response and reduced troponin T release in NSTEMI patients compared to placebo.

synapsesocial.com/papers/696308dd7247ee1819be2f36https://doi.org/10.1093/eurheartj/ehw171

Topics

Percutaneous coronary intervention
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abciximab Suppresses the Rise in Levels of Circulating Inflammatory Markers After Percutaneous Coronary Revascularization2001 · 196 citations
  2. 2Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection2010 · 194 citations
  3. 3ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation2011 · 3,095 citations
  4. 4The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis2012 · 1,186 citations
  5. 52015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation2015 · 8,337 citations